CHRS · Coherus Oncology, Inc.

Summary

Coherus Oncology, Inc. completed the sale of 28,600,000 shares of common stock at $1.75 per share to underwriters led by TD Securities (USA) LLC, Guggenheim Securities, LLC, and Oppenheimer & Co. Inc., receiving net proceeds of approximately $47.0 million after discounts. Underwriters have a 30-day option to purchase up to 4,290,000 additional shares for over-allotments.

Key takeaways

• Entered underwriting agreement on February 12, 2026 with TD Securities (USA) LLC, Guggenheim Securities, LLC, and Oppenheimer & Co. Inc.
• Issued and sold 28,600,000 shares of common stock on February 17, 2026.
• Public offering price: $1.75 per share; underwriter purchase price: $1.645 per share.
• Net proceeds: approximately $47.0 million after underwriter discounts and commissions.
• 30-day option for underwriters to purchase up to 4,290,000 additional shares.
• 60-day lock-up for Company directors, executive officers, and certain stockholders.